Cesca Therapeutics (NASDAQ: KOOL) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Cesca Therapeutics and Auxilium Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cesca Therapeutics 0 1 0 0 2.00
Auxilium Pharmaceuticals 0 0 0 0 N/A

Profitability

This table compares Cesca Therapeutics and Auxilium Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cesca Therapeutics -65.09% -28.32% -18.90%
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%

Volatility & Risk

Cesca Therapeutics has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Insider and Institutional Ownership

3.0% of Cesca Therapeutics shares are owned by institutional investors. 3.9% of Cesca Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cesca Therapeutics and Auxilium Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cesca Therapeutics $14.52 million 2.16 -$29.09 million ($0.91) -3.46
Auxilium Pharmaceuticals N/A N/A N/A ($3.27) -11.15

Auxilium Pharmaceuticals has lower revenue, but higher earnings than Cesca Therapeutics. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Cesca Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cesca Therapeutics beats Auxilium Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Cesca Therapeutics

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

About Auxilium Pharmaceuticals

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.